MAPT and Alzheimer disease: Although the deposition of amyloid plaques and tau phosphorylation are known to be neuropathological hallmarks of AD, the present study focused on changes in amyloid beta and neuroinflammation expression after PLX3397 treatment owing to lack of tau lesions in 5xFAD mice.